Update on management of cerebral venous thrombosis.
Journal
Current opinion in neurology
ISSN: 1473-6551
Titre abrégé: Curr Opin Neurol
Pays: England
ID NLM: 9319162
Informations de publication
Date de publication:
22 Oct 2024
22 Oct 2024
Historique:
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
aheadofprint
Résumé
This review intends to systematize the diagnostic and treatment approach to cerebral venous thrombosis (CVT), highlighting key studies that have been recently published. In light of the recent pandemic, new risk factors for CVT have emerged. Contrast-enhanced MRI and susceptibility-weighted imaging have been shown to offer increased sensitivity for detecting cortical vein thrombosis.Dabigatran seems to be as effective and well tolerated as warfarin for long-term anticoagulation. Partial venous recanalization often occurs in patients treated with anticoagulation only, as early as 8 days after treatment onset. For patients with CVT and impending brain herniation, two-thirds of those who undergo decompressive craniectomy survive, with one-third being functionally independent 6 months after diagnosis. CVT is an unusual type of cerebrovascular disease that mostly affects women of fertile age. Risk factors should be identified and addressed. Diagnosis relies on confirmation of venous sinus and/or vein thrombosis, usually by CT venography or MRI. Anticoagulation is the cornerstone of treatment. Despite the lack of high-quality evidence, endovascular treatment is often considered in severe cases. Special populations require tailored approaches. About 80% achieve mRS 0-1, but residual symptoms often affect quality of life and the ability to return to work.
Identifiants
pubmed: 39469812
doi: 10.1097/WCO.0000000000001329
pii: 00019052-990000000-00204
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Saposnik G, Barinagarrementeria F, Brown RD Jr, et al. on behalf of the American Heart Association Stroke Council and the Council on Epidemiology and Prevention Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42:1158–1192.
Miraclin TA, Prasad JD, Ninan GA, et al. Cerebral venous sinus thrombosis: changing trends in the incidence, age and gender (findings from the CMC Vellore CVT registry). Stroke Vasc Neurol 2024; 9:252–257.
Zhou LW, Yu AYX, Ngo L, Hill MD, Field TS. Incidence of Cerebral Venous Thrombosis: A Population-Based Study, Systematic Review, and Meta-Analysis. Stroke 2023; 54:169–177.
Ferro JM, Canhão P, Stam J, et al. ISCVT Investigators Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004; 35:664–670.
Otite FO, Patel S, Sharma R, et al. Trends in incidence and epidemiologic characteristics of cerebral venous thrombosis in the United States. Neurology 2020; 95:e2200–e2213.
Kyrle PA, Eichinger S. Is Virchow's triad complete? Blood 2009; 114:1138–1139.
Silvis SM, Middeldorp S, Zuurbier SM, et al. Risk factors for cerebral venous thrombosis. Semin Thromb Hemost 2016; 42:622–631.
Taquet M, Husain M, Geddes JR, et al. Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases. EClinicalMedicine 2021; 39:101061.
Baldini T, Asioli GM, Romoli M, et al. Cerebral venous thrombosis and severe acute respiratory syndrome coronavirus-2 infection: a systematic review and meta-analysis. Eur J Neurol 2021; 28:3478–3490.
Krzywicka K, van de Munckhof A, Sánchez van Kammen M, et al. Age-stratified risk of cerebral venous sinus thrombosis after SARS-CoV-2 vaccination. Neurology 2022; 98:e759–e768.
Sánchez van Kammen M, Aguiar de Sousa D, Poli S. Cerebral Venous Sinus Thrombosis With Thrombocytopenia Syndrome Study Group Characteristics and outcomes of patients with cerebral venous sinus thrombosis in SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. JAMA Neurol 2021; 78:1314–1323.
Netteland DF, Sandset EC, Mejlænder-Evjensvold M, et al. Cerebral venous sinus thrombosis in traumatic brain injury: A systematic review of its complications, effect on mortality, diagnostic and therapeutic management, and follow-up. Front Neurol 2023; 13:1079579.
Southwick FS, Richardson EP Jr, Swartz MN. Septic thrombosis of the dural venous sinuses. Medicine (Baltimore) 1986; 65:82–106.
Kastenbauer S, Pfister HW. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain 2003; 126 (Pt 5):1015–1025.
Pfister HW, Borasio GD, Dirnagl U, et al. Cerebrovascular complications of bacterial meningitis in adults. Neurology 1992; 42:1497–1504.
Schievink WI, Maya MM. Cerebral venous thrombosis in spontaneous intracranial hypotension. Headache 2008; 1511–1519.
Ferrante E, Trimboli M, Petrecca G, Allegrini F. Cerebral venous thrombosis in spontaneous intracranial hypotension: a report of 8 cases and review of the literature. J Neurol Sci 2021; 425:117467.
Stam J. Thrombosis of the cerebral veins and sinuses. N Engl JMed 2005; 352:1791–1798.
Sinnaeve L, Vanopdenbosch L, Paemeleire K. Association of cerebral venous thrombosis and intracranial hypotension: review of 3 cases. J Stroke Cerebrovasc Dis 2017; 26:e165–e169.
Lindgren E, Rentzos A, Hiltunen S, et al. Dural arteriovenous fistulas in cerebral venous thrombosis: data from the International Cerebral Venous Thrombosis Consortium. Eur J Neurol 2022; 29:761–770.
Tsai LK, Jeng JS, Liu HM, et al. Intracranial dural arteriovenous fistulas with or without cerebral sinus thrombosis: analysis of 69 patients. J Neurol Neurosurg Psychiatry 2004; 75:1639–1641.
Al-Shahi R, Bhattacharya JJ, Currie DG, et al. Scottish Intracranial Vascular Malformation Study Collaborators Prospective, population-based detection of intracranial vascular malformations in adults: the Scottish Intracranial Vascular Malformation Study (SIVMS). Stroke 2003; 34:1163–1169.
Ferro JM, Canhão P, Aguiar de Sousa D. Cerebral venous thrombosis. Presse Med 2016; 45 (12 Pt 2):e429–e450.
Alet M, Ciardi C, Alemán A, et al. Cerebral venous thrombosis in Argentina: clinical presentation, predisposing factors, outcomes and literature review. J Stroke Cerebrovasc Dis 2020; 29:105145.
Martinelli I, Bucciarelli P, Passamonti SM, et al. Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation 2010; 121:2740–2746.
Yaghi S, Shu L, Bakradze E, et al. Direct oral anticoagulants versus warfarin in the treatment of cerebral venous thrombosis (ACTIONCVT): a multicenter international study. Stroke 2022; 53:728–738.
Lindgren E, Silvis SM, Hiltunen S, et al. Acute symptomatic seizures in cerebral venous thrombosis. Neurology 2020; 95:e1706–e1715.
Haage P, Krings T, Schmitz-Rode T. Nontraumatic vascular emergencies: imaging and intervention in acute venous occlusion. Eur Radiol 2002; 12:2627–2643.
Virapongse C, Cazenave C, Quisling R, et al. The empty delta sign: frequency and significance in 76 cases of dural sinus thrombosis. Radiology 1987; 162:779–785.
Alajmi E, Zung J, Duquet-Armand M, et al. Prevalence of venous infarction in patients with cerebral venous thrombosis: baseline diffusion-weighted MRI and follow-up MRI. Stroke 2023; 54:1808–1814.
Xu W, Gao L, Li T, et al. The performance of CT versus MRI in the differential diagnosis of cerebral venous thrombosis. Thromb Haemost 2018; 118:1067–1077.
Idbaih A, Boukobza M, Crassard I, et al. MRI of clot in cerebral venous thrombosis: high diagnostic value of susceptibility-weighted images. Stroke 2006; 37:991–995.
Pai V, Khan I, Sitoh YY, Purohit B. Pearls and pitfalls in the magnetic resonance diagnosis of dural sinus thrombosis: a comprehensive guide for the trainee radiologist. J Clin Imaging Sci 2020; 10:77.
Dmytriw AA, Song JSA, Yu E, Poon CS. Cerebral venous thrombosis: state of the art diagnosis and management. Neuroradiology 2018; 60:669–685.
Aguiar de Sousa D, Lucas Neto L, Jung S, et al. Brush sign is associated with increased severity in cerebral venous thrombosis. Stroke 2019; 50:1574–1577.
Sadik JC, Jianu DC, Sadik R, et al. Imaging of cerebral venous thrombosis. Life (Basel) 2022; 12:1215.
Ota T. Functional cerebral venous anatomy from the viewpoint of venous collaterals Part I, supratentorial superficial and deep venous system. Stroke 2024; 4:e001050.
Aguiar de Sousa D, Lucas Neto L, Arauz A, et al. Early recanalization in patients with cerebral venous thrombosis treated with anticoagulation. Stroke 2020; 51:1174–1181.
Ducreux D, Oppenheim C, Vandamme X, et al. Diffusion-weighted imaging patterns of brain damage associated with cerebral venous thrombosis. Am J Neuroradiol 2001; 22:261–268.
Coutinho JM, van den Berg R, Zuurbier SM, et al. Small juxtacortical hemorrhages in cerebral venous thrombosis. Ann Neurol 2014; 75:908–916.
Aguiar de Sousa D, Lucas Neto L, Canhão P, Ferro JM. Recanalization in cerebral venous thrombosis: a systematic review and meta-analysis. Stroke 2018; 49:1828–1835.
Kim DJ, Honig A, Alimohammadi A, et al. Recanalization and outcomes after cerebral venous thrombosis: a systematic review and meta-analysis. Res Pract Thromb Haemost 2023; 7:100143.
Ferro JM, Bousser MG, Canhão P, et al. European Stroke Organization European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European academy of neurology. Eur Stroke J 2017; 2:195–221.
Saposnik G, Bushnell C, Coutinho JM, et al. Diagnosis and management of cerebral venous thrombosis: a Scientific Statement from the American Heart Association. Stroke 2024; 55:e77–90.
Aguiar de Sousa D, Ferro JM, Canhão P, et al. ISCVT Investigators Cerebral venous thrombosis causing posterior fossa lesions: description of a case series and assessment of safety of anticoagulation. Cerebrovasc Dis 2014; 38.5:384–388.
Field TS, Dizonno V, Almekhlafi MA, et al. SECRET Investigators Study of rivaroxaban for cerebral venous thrombosis: a randomized controlled feasibility trial comparing anticoagulation with rivaroxaban to standard-of care in symptomatic cerebral venous thrombosis. Stroke 2023; 54:2724–2736.
Ferro JM, Coutinho JM, Dentali F, et al. RE-SPECT CVT Study Group Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial. JAMA Neurol 2019; 76:1457–1465.
Ferro JM, Crassard I, Coutinho JM, et al. Second International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT 2) Investigators Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data. Stroke 2011; 42:2825–2831.
Aaron S, Ferreira J, Coutinho J, et al. Outcomes of decompressive surgery for patients with severe cerebral venous thrombosis. Results of the DECOMPRESS2 study. Stroke 2024; 55:1218–1226.
Coutinho JM, Zuurbier SM, Bousser MG, et al. TO-ACT investigators Effect of endovascular treatment with medical management vs standard care on severe cerebral venous thrombosis: the TO-ACT randomized clinical trial. JAMA Neurol 2020; 77:966–973.
Bello N, Meyers KJ, Workman J, et al. Systematic literature review and meta-analysis of venous thromboembolism events in systemic lupus erythematosus. Rheumatol Ther 2023; 10:7–34.
Aguiar de Sousa D, Mestre T, Ferro JM. Cerebral venous thrombosis in Behçet's disease: a systematic review. J Neurol 2011; 258:719–727.
MacFarlane JT, Cleland PG, Attai ED, Greenwood BM. Failure of heparin to alter the outcome of pneumococcal meningitis. BMJ 1977; 2:1522.
Mook-Kanamori BB, Fritz D, Brouwer MC, et al. Intracerebral hemorrhages in adults with community associated bacterial meningitis in adults: should we reconsider anticoagulant therapy? PLoS One 2012; 7:e45271.
Sutter PA, Anderson MG, Sahyouni R, et al. Anticoagulation for the treatment of septic cerebral venous sinus thrombosis in the setting of pediatric sinogenic and otogenic intracranial infections. Neurosurg focus 2023; 55:E8.
Deliran SS, Brouwer MC, Coutinho JM, Beek DV. Bacterial meningitis complicated by cerebral venous thrombosis. Eur Stroke J 2020; 5:394–401.
Zuurbier SM, Coutinho JM, Stam J, et al. IISCVT Investigators Clinical outcome of anticoagulant treatment in head or neck infection-associated cerebral venous thrombosis. Stroke 2016; 47:1271–1277.
Connor P, Sánchez van Kammen M, Lensing AWA, et al. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Adv 2020; 4:6250–6258.
Yaghi S, Saldanha IJ, Misquith C, et al. Direct oral anticoagulants versus vitamin K antagonists in cerebral venous thrombosis: a systematic review and meta-analysis. Stroke 2022; 53:3014–3024.
van de Munckhof A, Sánchez van Kammen M, Krzywicka K, et al. Direct oral anticoagulants for the treatment of cerebral venous thrombosis – a protocol of an international phase IV study. Front Neurol 2023; 14:1251581.
Miranda B, Aaron S, Arauz A, et al. The benefit of EXtending oral antiCOAgulation treatment (EXCOA) after acute cerebral vein thrombosis (CVT): EXCOA-CVT cluster randomized trial protocol. Int J Stroke 2018; 13:771–774.
Simes J, Becattini C, Agnelli G, et al. Aspirin for the prevention of recurrent venous thromboembolism. Circulation 2014; 130:1062–1071.
Becattini C, Agnelli G, Schenone A, et al. WARFASA Investigators Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366:1959–1967.
Martinelli I, Lensing AW, Middeldorp S, et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 2016; 127:1417–1425.
Christiansen SC, Lijfering WM, Helmerhorst FM, et al. Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event. J Thromb Haemost 2010; 8:2159–2168.
Zuurbier SM, Hiltunen S, Tatlisumak T, et al. Admission hyperglycemia and clinical outcome in cerebral venous thrombosis. Stroke 2016; 47:390–396.
Bugnicourt JM, Guegan-Massardier E, Roussel M, et al. Cognitive impairment after cerebral venous thrombosis: a two-center study. J Neurology 2013; 260:1324–1331.
de Bruijn SF, Budde M, Teunisse S, et al. Long-term outcome of cognition and functional health after cerebral venous sinus thrombosis. Neurology 2000; 54:1687–1689.
Buccino G, Scoditti U, Patteri I, et al. Neurological and cognitive long-term outcome in patients with cerebral venous sinus thrombosis. Acta Neurol Scand 2003; 107:330–335.
Sánchez van Kammen M, Lindgren E, Silvis SM, et al. Late seizures in cerebral venous thrombosis. Neurology 2020; 95:e1716–e1723.
Palazzo P, Agius P, Ingrand P, et al. Venous thrombotic recurrence after cerebral venous thrombosis: a long-term follow-up study. Stroke 2017; 48:321–326.
Miranda B, Ferro JM, Canhão P, et al. ISCVT Investigators Venous thromboembolic events after cerebral vein thrombosis. Stroke 2010; 41:1901–1906.
Dentali F, Poli D, Scoditti U, et al. CErebral VEin Thrombosis International Study Investigators Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost 2012; 10:1297–1302.
Lim HY, Ng C, Donnan G, et al. Ten years of cerebral venous thrombosis: male gender and myeloproliferative neoplasm is associated with thrombotic recurrence in unprovoked events. J Thromb Thrombolysis 2016; 42:423–443.
Pires GS, Ribeiro DD, Oliveira JAQ, et al. Risk factors associated with recurrent venous thromboembolism after a first cerebral venous thrombosis event: a cohort study. Thromb Res 2019; 178:85–90.
Aguiar de Sousa D, Canhão P, Ferro JM. Safety of pregnancy after cerebral venous thrombosis: a systematic review. Stroke 2016; 47:713–718.
Khan M, Arauz A, Uluduz D, et al. VENOST Study Group Predictors of mortality and functional outcome in pregnancy and puerperium-related cerebral venous thrombosis. Cerebrovasc Dis 2023; 52:393–400.
Fang T, Shu L, Elnazeir M, et al. ACTION-CVT Study Collaborators Characteristics and outcomes of postpartum cerebral venous sinus thrombosis: a subgroup analysis of the ACTION-CVT study. J Stroke Cerebrovasc Dis 2022; 31:106865.
Aguiar de Sousa D, Canhão P, Ferro JM. Safety of pregnancy after cerebral venous thrombosis: systematic review update. J Neurol 2018; 265:211–212.
Aguiar de Sousa D, Canhão P, Crassard I, et al. Safety of pregnancy after cerebral venous thrombosis: results of the ISCVT (International Study on Cerebral Vein and Dural Sinus Thrombosis)-2 PREGNANCY Study. Stroke 2017; 48:3130–3133.
Santos M, Aguiar de Sousa D. Cerebrovascular disease in pregnancy and postpartum. Curr Opin Neurol 2022; 35:31–38.
Otite FO, Vanguru H, Anikpezie N, et al. Contemporary incidence and burden of cerebral venous sinus thrombosis in children of the United States. Stroke 2022; 53:e496–e499.
Connor P, Sanchez van Kammen M, Lensing AWA, et al. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Adv 2020; 4:6250–6258.
Goldenberg NA, Kittelson JM, Abshire TC, et al. Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous thromboembolism: the Kids-DOTT randomized clinical trial. JAMA 2022; 327:129–137.
Ferro JM, Sousa DAD, Coutinho JM, Martinelli I. European stroke organization interim expert opinion on cerebral venous thrombosis occurring after SARS-CoV-2 vaccination. Eur Stroke J 2021; 6:116–121.